May 22 |
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
|
May 16 |
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
|
May 15 |
Editas Medicine: Promising Milestone Achieved But Be Patient
|
May 14 |
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
|
May 14 |
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
|
May 12 |
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
May 10 |
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
|
May 9 |
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
|
May 9 |
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
|
May 9 |
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
|